1 / 7

Understanding Lung Cancer: Types, Statistics, and Treatment Approaches

This overview highlights key statistics and classifications of lung cancer, focusing on the two main types: Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). NSCLC accounts for 85.3% of lung cancer cases and is further divided into adenocarcinoma (40.1%), squamous cell carcinoma (21.4%), large cell carcinoma (2.6%), and other types (20.2%). Each subtype has distinct characteristics and treatment implications, particularly regarding genetic mutations. Awareness and understanding of lung cancer are crucial for prevention and treatment.

lance
Télécharger la présentation

Understanding Lung Cancer: Types, Statistics, and Treatment Approaches

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Slides last updated: October 2013

  2. There are two main types of lung cancer1 • Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013, accessed on 15/09/2013.

  3. NSCLC can be further divided into different sub-types1 Large cell carcinoma (2.6% of lung cancer) Lung Cancer (100%) Other NSCLC (20.2% of lung cancer) Squamous cell carcinoma (21.4% of lung cancer) Adenocarcinoma (40.1% of lung cancer) NSCLC (85.3% of lung cancer) • Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013, accessed on 15/09/2013.

  4. NSCLC: Adenocarcinoma 40.1%1 Adenocarcinoma Adenocarcinoma lesions are usually peripherally located2 Most frequent in women and non-smokers2 Some patients have EGFR/ErbB1 mutations; these patients require a specific diagnosis and treatment approach3 1. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013, accessed on 15/09/2013. 2. Heighway J & Betticher DC. Atlas Genet Cytogenet Oncol Haematol. February 2004. 3. Vijayalakshmi R, et al. Indian J Surg Oncol 2011;2:178‒188.

  5. NSCLC: Squamous cell carcinoma 21.4%1 Squamous Cell Carcinoma2 Squamous Cell Carcinoma lesions are generally centrally located, near bronchi Tends to spread locally Closely correlated with smoking 1. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013, accessed on 15/09/2013. 2. Heighway J & Betticher DC. Atlas Genet Cytogenet Oncol Haematol. February 2004.

  6. NSCLC: Large cell carcinoma 2.6%1 Large Cell Carcinoma Comprised of undifferentiated cells 2 Lesions are usually peripherally located but can occur anywhere 2 High tendency to metastasize2 1. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013, accessed on 15/09/2013. 2. Heighway J & Betticher DC. Atlas Genet Cytogenet Oncol Haematol. February 2004.

  7. NSCLC: Other 20.2%1 Other, including Not Otherwise Specified (NOS) or Unknown A classification of NOS or unknown is usually due to ineffective sampling and examination2 This classification is expected to decline in use due to more accurate biopsies and advances in immunohistochemistry and biomarker testing2 1. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013, accessed on 15/09/2013. 2. Righi L, Graziano P, Fornari A, et al. Cancer 2011;117:3416‒3423.

More Related